A Comparison of Study Designs of Inhaled Agents in Non-Cystic Fibrosis Bronchiectasis (NCFB): Key Differences in the Phase 3 RESPIRE Trials of Ciprofloxacin Dry Powder for Inhalation (DPI)

被引：0
|
作者：
Aksamit, Timothy [1 ]
De Soyza, Anthony [1 ]
Operschall, Elisabeth [1 ]
Bandel, Tiemo-Joerg [1 ]
Wilson, Robert [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
CHEST | 2015年 / 148卷 / 04期
关键词：
D O I：
10.1378/chest.2277297
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
662A
引用
收藏
页数：2
相关论文
共 39 条
  • [1] Baseline Demographic Profile Of Subjects Of The Phase 3 Respire 2 Trial Of Ciprofloxacin Dry Powder For Inhalation (dpi) In Non-Cystic Fibrosis Bronchiectasis (ncfb)
    Aksamit, T. R.
    De Soyza, A.
    Operschall, E.
    Bandel, T. -J.
    Krahn, U.
    Montegriffo, E.
    Criollo, M.
    Wilson, R. C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [2] The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis
    Aksamit, Timothy
    Bandel, Tiemo-Joerg
    Criollo, Margarita
    De Soyza, Anthony
    Elborn, J. Stuart
    Operschall, Elisabeth
    Polverino, Eva
    Roth, Katrin
    Winthrop, Kevin L.
    Wilson, Robert
    CONTEMPORARY CLINICAL TRIALS, 2017, 58 : 78 - 85
  • [3] The Impact of Exacerbation Definition in Non-Cystic Fibrosis Bronchiectasis (NCFB) Studies: Results from the RESPIRE Trials of Ciprofloxacin Dry Powder for Inhalation (DPI) Using Different Definitions of Exacerbation
    Aksamit, T.
    Bandel, T.
    De Soyza, A.
    Elborn, S.
    Operschall, E.
    Winthrop, K.
    Wilson, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [4] LATE-BREAKING ABSTRACT: Baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB)
    De Soyza, Anthony
    Aksamit, Timothy
    Operschall, Elisabeth
    Bandel, Tiemo-Joerg
    Krahn, Ulrike
    Criollo, Margarita
    Wilson, Robert
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [5] Effects Of Ciprofloxacin Dry Powder For Inhalation (ciprofloxacin Dpi) On Health-Related Quality Of Life In Patients With Non-Cystic Fibrosis Bronchiectasis (ncfb): Results From The Phase Iii Respire 1 Study
    Quittner, A.
    De Soyza, A.
    Aksamit, T. R.
    Bandel, T. -J.
    Criollo, M.
    Elborn, J.
    Filonenko, A.
    Krahn, U.
    Lau, M.
    Operschall, E.
    Polverino, E.
    Roth, K.
    Winthrop, K. L.
    Wilson, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [6] Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis
    De Soyza, Anthony
    Aksamit, Timothy
    EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (08): : 875 - 884
  • [7] Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study
    Wilson, Robert
    Welte, Tobias
    Polverino, Eva
    De Soyza, Anthony
    Greville, Hugh
    O'Donnell, Anne
    Alder, Jeff
    Reimnitz, Peter
    Hampel, Barbara
    EUROPEAN RESPIRATORY JOURNAL, 2013, 41 (05) : 1107 - 1115
  • [8] RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis
    De Soyza, Anthony
    Aksamit, Timothy
    Bandel, Tiemo-Joerg
    Criollo, Margarita
    Elborn, J. Stuart
    Operschall, Elisabeth
    Polverino, Eva
    Roth, Katrin
    Winthrop, Kevin L.
    Wilson, Robert
    EUROPEAN RESPIRATORY JOURNAL, 2018, 51 (01)
  • [9] Ciprofloxacin Dry Powder for Inhalation: Inspiratory Flow in Patients with Non-cystic Fibrosis Bronchiectasis
    Stass, Heino
    Nagelschmitz, Johannes
    Kappeler, Dominik
    Sommerer, Knut
    Patzlaff, Astrid
    Weimann, Boris
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2019, 32 (03) : 156 - 163
  • [10] Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomized study
    Antoniu, Sabina
    Azoicai, Doina
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (05) : 671 - 673
1234